Last reviewed · How we verify
Atazanavir, ritonavir, lamivudine
Atazanavir, ritonavir, lamivudine is a Antiretroviral combination (protease inhibitor + NRTI) Small molecule drug developed by Catholic University of the Sacred Heart. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy. Also known as: Lamivudine (Epivir, GSK), Atazanavir (Reyataz, BMS), Ritonavir (Norvir, Abbott).
This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps.
This combination inhibits HIV protease and reverse transcriptase to block viral replication at multiple steps. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy.
At a glance
| Generic name | Atazanavir, ritonavir, lamivudine |
|---|---|
| Also known as | Lamivudine (Epivir, GSK), Atazanavir (Reyataz, BMS), Ritonavir (Norvir, Abbott) |
| Sponsor | Catholic University of the Sacred Heart |
| Drug class | Antiretroviral combination (protease inhibitor + NRTI) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Atazanavir and ritonavir are protease inhibitors that prevent HIV protease from cleaving viral polyproteins, while lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks reverse transcriptase activity. Together, they suppress HIV replication by targeting two critical enzymes in the viral lifecycle, reducing viral load and slowing disease progression.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- HIV-1 infection as part of combination antiretroviral therapy
Common side effects
- Hyperbilirubinemia
- Jaundice
- Nausea
- Diarrhea
- Headache
- Rash
- Nephrolithiasis
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia (NA)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) (PHASE3)
- Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC (PHASE3)
- Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atazanavir, ritonavir, lamivudine CI brief — competitive landscape report
- Atazanavir, ritonavir, lamivudine updates RSS · CI watch RSS
- Catholic University of the Sacred Heart portfolio CI
Frequently asked questions about Atazanavir, ritonavir, lamivudine
What is Atazanavir, ritonavir, lamivudine?
How does Atazanavir, ritonavir, lamivudine work?
What is Atazanavir, ritonavir, lamivudine used for?
Who makes Atazanavir, ritonavir, lamivudine?
Is Atazanavir, ritonavir, lamivudine also known as anything else?
What drug class is Atazanavir, ritonavir, lamivudine in?
What development phase is Atazanavir, ritonavir, lamivudine in?
What are the side effects of Atazanavir, ritonavir, lamivudine?
What does Atazanavir, ritonavir, lamivudine target?
Related
- Drug class: All Antiretroviral combination (protease inhibitor + NRTI) drugs
- Target: All drugs targeting HIV protease, HIV reverse transcriptase
- Manufacturer: Catholic University of the Sacred Heart — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Indication: Drugs for HIV-1 infection as part of combination antiretroviral therapy
- Also known as: Lamivudine (Epivir, GSK), Atazanavir (Reyataz, BMS), Ritonavir (Norvir, Abbott)
- Compare: Atazanavir, ritonavir, lamivudine vs similar drugs
- Pricing: Atazanavir, ritonavir, lamivudine cost, discount & access